Development of standard definitions and grading for Maternal and Fetal Adverse Event Terminology

Rebecca N. Spencer1,2 | Kurt Hecher3 | Gill Norman4,5 | Karel Marsal6 | Jan Deprest2,7 | Alan Flake8 | Francesc Figueras9,10 | Christoph Lees11 | Steve Thornton2,7 | Kathleen Beach13 | Marcy Powell14 | Fatima Crispi10,9 | Anke Diemert15 | Neil Marlow2 | Donald M. Peebles2,16 | Magnus Westgren17 | Helena Gardiner18 | Eduard Gratacos10,19 | Jana Brodszki6 | Albert Batista9 | Helen Turier20 | Mehali Patel21,22 | Beverley Power23 | James Power23 | Gillian Yaz24 | Anna L. David2,16

1School of Medicine, University of Leeds, Leeds, UK
2Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, UK
3Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4Division of Nursing, Midwifery & Social Work, Faculty of Biology, Medicine and Health, School of Health Sciences, University of Manchester, Manchester, UK
5Antenatal Results and Choices Charity, UK
6Lund University, Lund, Sweden
7Department of Development and Regeneration, KU Leuven, Leuven, Belgium
8Department of Surgery, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
9Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
10BCNatal – Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Deu), University of Barcelona, Spain
11Queen Charlottes and Chelsea Hospital, Imperial College London, London, UK
12Queen Mary University of London, London, UK
13Global Health Unit, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
14Safety and Medical Governance, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
15Clinic for Obstetrics and Prenatal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16NIHR UCLH Biomedical Research Centre, London, UK
17Karolinska Institute, Stockholm, Sweden
18The Fetal Center, UTHealth McGovern Medical School, Houston, Texas, USA
19Center for Biomedical Research on rare Diseases (CIBERER), Institut D’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
20Twins Trust Charity, Aldershot, UK
21Bliss Charity, London, UK
22Sands Charity, London, UK
23CDH UK: The Congenital Diaphragmatic Hernia Support Charity, King’s Lynn, UK
24SHINE: Spina bifida, Hydrocephalus, Information, Networking, Equality Charity, Peterborough, UK

The data was presented as part of a plenary that I gave at the 2021 ISPD virtual conference presentation on fetal therapy.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
Abstract

Objective: Adverse event (AE) monitoring is central to assessing therapeutic safety. The lack of a comprehensive framework to define and grade maternal and fetal AEs in pregnancy trials severely limits understanding risks in pregnant women. We created AE terminology to improve safety monitoring for developing pregnancy drugs, devices and interventions.

Method: Existing severity grading for pregnant AEs and definitions/indicators of ‘severe’ and ‘life-threatening’ conditions relevant to maternal and fetal clinical trials were identified through a literature search. An international multidisciplinary group identified and filled gaps in definitions and severity grading using Medical Dictionary for Regulatory Activities (MedDRA) terms and severity grading criteria based on Common Terminology Criteria for Adverse Event (CTCAE) generic structure. The draft criteria underwent two rounds of a modified Delphi process with international fetal therapy, obstetric, neonatal, industry experts, patients and patient representatives.

Results: Fetal AEs were defined as being diagnosable in utero with potential to harm the fetus, and were integrated into MedDRA. AE severity was graded independently for the pregnant woman and her fetus. Maternal (n = 12) and fetal (n = 19) AE definitions and severity grading criteria were developed and ratified by consensus.

Conclusions: This Maternal and Fetal AE Terminology version 1.0 allows systematic consistent AE assessment in pregnancy trials to improve safety.

Key points

What's already known about this topic?
- Adverse event (AE) monitoring is central to assessing therapeutic safety. The lack of a comprehensive AE framework in pregnancy trials severely limits understanding risks in pregnant women.

What does this study add?
- Through international consensus we systematically developed definitions and severity grading for maternal and foetal AEs: Maternal and Fetal AE Terminology Version 1.0. New fetal AE definitions were adopted by the Medical Dictionary for Regulatory Activities. This terminology should be used to monitor safety in pregnancy trials.

1 | INTRODUCTION

Conducting clinical trials in pregnancy raises many challenges, primarily due to safety concerns for mother and fetus, and particularly when testing novel maternal and fetal therapies. The legacy of thalidomide and diethylstilbestrol, combined with more recent regulatory categorisation of pregnant women as vulnerable, has largely excluded this population, even limiting the inclusion of females of reproductive potential from clinical trials of novel therapies. An AE is ‘any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this product’. AE definitions are important signals in clinical trials, facilitating swift and responsible communication of safety data between study investigators, sponsors and regulators. Regulatory guidelines require that AEs are recorded in medical records, reported to the sponsor and competent authority, and determination made as to whether they (a) meet European Medicines Agency (EMA)/ Food and Drug Administration (FDA)/ Medicines and Healthcare products Regulatory Agency (MHRA) definition of ‘serious’ and (b) are related to the administration of the Investigational Medical Product (IMP). This determines classification as a serious adverse reaction (SAR) (Figure S1).

Severity of AEs should be recorded using standard grading criteria. An example of why standardisation is so critical is when
decisions around dose-escalation and the Maximum Tolerated Dose (MTD) are based on observation of Adverse Reactions (ARs) of given severity. The most widely used system, the Common Terminology Criteria for Adverse Events (CTCAE) (Version 5.0) comprises 837 potential AE, of which only 4 relate to ‘pregnancy, the puerperium and perinatal conditions’. Some condition-specific severity grading for pregnancy-specific events have been developed (e.g., in HIV-AIDS and surgery). However, there remain no standard general severity grading criteria. This contrasts with recent Delphi consensus work to integrate neonatal terminology and definitions into wider dictionaries. We convened an international multidisciplinary group to develop standard definitions and severity grading criteria to enable objective reporting of AEs in all clinical trials involving pregnant women.

2 | METHODS

We undertook a stepwise consensus process through a Delphi approach, between January 2015 and December 2019 (Figure 1). Following a comprehensive review of existing terminology, consensus statements and guidelines, draft maternal and fetal AE definitions and severity grading criteria were agreed by the Steering Group. New fetal AE terms were integrated with MedDRA (Medical Dictionary for Regulatory Activities) requirements and added to MedDRA terms list. The draft fetal and maternal AE definitions and severity criteria were reviewed by a Patient Public Advisory Group (PPAG) before undergoing a two-stage international modified Delphi consensus process. A final set of maternal and fetal AE definitions and severity criteria were agreed.

2.1 | Phase 1: state of the art

2.1.1 | Review of existing AE terminology

In January 2015, we consulted internationally with academic and industry pregnancy and fetal therapy clinical triallists to identify existing maternal and fetal AE definitions and severity grading criteria for clinical trials in pregnancy (Table S1). Existing definitions and severity grading criteria were reviewed with MedDRA preferred terms for AEs.

2.1.2 | Review of consensus statements and guidelines literature

In March 2015, we performed a literature review to identify existing definitions and severity descriptors for maternal and fetal AEs in consensus development conferences, statements and practice guidelines (Figure S2). Between March and April 2015, the National Guideline Clearing House, International Guideline Library and Scottish Intercollegiate Guidelines Network were searched for pregnancy or neonatal care guidelines. Full guideline lists from National Colleges and Professional Societies were hand-searched (Table S2); key references were retrieved (March–April 2015)

![FIGURE 1 An overview of the three-stage development process of the standard maternal and fetal AE severity grading criteria. Stakeholder involvement is indicated by C (clinicians), S (scientists), I (industry), M (midwifery representatives), P (patient and/or charity representatives) and R (regulatory authority employees). MedDRA, Medical Dictionary for Regulatory Activities; MSSO, Maintenance and Support Services Organisation; PPAG, Patient Public Advisory Group; SG, EVERREST AE Consensus Steering Group [Colour figure can be viewed at wileyonlinelibrary.com]](image-url)
and reviewed for definitions and severity indicators (Table S3).10,11,17-62

2.2 | Phase 2: developing preliminary criteria

2.2.1 | Development of the preliminary AE definitions and severity grading criteria

The EVEREST AE Consensus Steering Group met in May 2015. Maternal AE definitions and severity grading criteria were developed based on relevant sections of the reviewed AE terminology and literature, starting with CTCAE generic grading criteria (Table 1). For fetal AEs a generic severity grading system was developed. Fetal AEs were identified by considering the potential impacts of maternal or fetal therapies on fetal organ systems. The effects of maternal AEs on the fetus were also considered. AE definitions were adapted from existing clinical definitions in the literature.

2.2.2 | Integration into MedDRA terminology

In September 2015, the Steering Group met with the Chief Medical Officer for the MedDRA Maintenance and Support Services Organisation (MSSO) to amend and integrate fetal AE terms with existing MedDRA terms, hierarchy, structure and functioning (https://www.meddra.org/).

### TABLE 1  Agreed generic criteria for grading the severity of fetal AEs (top table)

| Agreed generic grading of foetal AEs | Grade 1 (mild) | Grade 2 (moderate) | Grade 3 (severe) | Grade 4 (life-threatening) | Grade 5 (death) |
|-------------------------------------|----------------|-------------------|-----------------|---------------------------|----------------|
| Clinical observation of uncertain significance; resolves spontaneously with low risk of long-term consequences | Likely to resolve spontaneously with low risk of long-term consequences; requires increased frequency of monitoring, but less than once a week; requires additional tests | Requires increased frequency of monitoring, once a week or more; likely to lead to significant neonatal morbidity | Likely to lead to fetal injury or permanent disability; likely to lead to neonatal death; requiring a substantive change in management including changing the course of an interventional procedure or necessitating delivery | Fetal death |

### CTCAE generic severity grading for comparison

| | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---|-------------------------------|---------|---------|--------|--------|
| Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated | Moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living | Severe or medically significant but not immediately life-threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting self-care activities of daily living | Life-threatening consequences; urgent intervention indicated | Death related to AE |

Note: The Common Terminology Criteria for Adverse Events (CTCAE) generic severity grading criteria are listed in the bottom table and will apply to maternal AEs. A semicolon indicates ‘or’ within the description of the grade.

Abbreviation: AE, adverse event.

2.2.3 | Review by Patient Public Advisory Group

In October 2016, the Steering Group presented preliminary AE definitions and severity grading criteria to the Guided Instrumentation for Fetal Therapy and Surgery (GIFT-Surg) project PPAG (www.GIFT-Surg.ac.uk) with representatives from UK charities supporting patients with fetal abnormalities and pregnancy complications, together with neonatologists, obstetric, fetal medicine and fetal surgery clinicians (Figure S3). The PPAG considered the definitions and criteria, proposing recommendations for good practice in clinical trials during pregnancy.

2.3 | Phase 3: refining and finalising the criteria

2.3.1 | Modified Delphi consensus process

The preliminary maternal and fetal AE definitions and severity grading criteria underwent a modified Delphi consensus process. Two rounds of online surveys were followed by Steering Group resolution of outstanding issues. Participants with expertise relevant to maternal and/or fetal AEs were identified by the Steering Group, including maternal and fetal medicine specialists, obstetricians, paediatric and fetal surgeons, neonatologists, clinical trialists, research midwives, fetal physiologists and pregnancy charity representatives. We ensured broad global coverage inviting participants from Europe, United States and Canada, South America, Middle East, Asia, Australasia and Africa. For each component of
each severity grading criterion, participants had the option to: keep the criterion at the proposed level of severity; downgrade it to a different severity (if applicable); remove it from the criteria.

Delphi participation was tracked through individual login details. In February 2018, we launched the first round for both maternal and fetal AE surveys which closed in August 2018 following three reminders. The second round launched in September 2019, closing in November 2019 after two reminders. Agreement of ≥70% participants was taken as consensus. Systematically missing responses where participants stopped part-way through the survey were excluded from analysis; non-systematically missing responses were included as non-agreement.

2.3.2 | Steering Group consensus meeting

The Steering Group finally convened to review Delphi consensus results (December 2019) and to resolve outstanding questions before agreeing a final set of maternal and fetal AE definitions and severity criteria.

3 | RESULTS

3.1 | Phase 1: state of the art

3.1.1 | Review of existing AE terminology

Four sets of national or international AE severity grading criteria and a fifth set of industry criteria were reviewed by the Steering Group; the first four were not specifically pregnancy related AE systems. Two included no pregnancy-specific AEs63,64 and the other three were considered insufficient to meet the needs of trials of maternal and fetal therapies, particularly as few fetal AEs were included.10,11,65 MedDRA AE terms for ‘fetal complications’ were limited and related generally to teratogenic effects, or fetal malposition and malpresentation in labour.

3.1.2 | Review of consensus statements and guidelines literature

Handsearching full lists of guidelines from National Colleges and Professional Societies (Table S2) and the literature search of consensus statements and guidelines (March–April 2015) identified maternal AEs that were grouped into 10 categories. Identified documents were examined for definitions of AE terms and criteria used to indicate their severity. A summary was prepared for the Steering Group before the first meeting (Table S3).

3.2 | Phase 2: developing preliminary criteria

3.2.1 | Development of preliminary AE definitions and severity grading criteria

The Steering Group considered general principles of assessing AE severity in pregnancy and the ways that this might differ from assessment in a non-pregnant population. Firstly, fetal AEs must be diagnosable in utero, with the potential, at their most severe, to cause a detrimental effect in utero. Current methods of investigating the fetus (imaging and fetal heart rate monitoring) and predicting short- and long-term prognosis can be challenging, potentially making it impossible to differentiate between mild and moderate events and between severe and life-threatening events. Therefore, the Steering Group decided that some AEs may only have severity criteria defined for grade 2 (moderate) and grade 4 (life-threatening), with grade 3 remaining undefined. AEs that only manifest after birth were considered to be neonatal AEs, even if they had originated in utero. For fetal AEs ‘hospitalisation or prolongation of hospitalisation’, which forms part of the CTCAE general criteria, was considered a poor indicator of severity. Maternity units often have a low threshold for admitting pregnant women to observe fetal well-being. In contrast, a well pregnant woman with a severely compromised fetus may be managed as an outpatient, in cases where fetal intervention is not deemed appropriate. A more useful indicator of fetal severity was considered to be a requirement for a change in pregnancy management, including additional fetal intervention, for example, blood transfusion, or delivery including termination of pregnancy. Generic criteria to assess fetal AE severity were developed (Table 1) based on the CTCAE generic criteria; the CTCAE generic criteria were assumed to apply to maternal AE severity.

Next the Steering Group decided that, in order to fully characterise the impact of any investigational intervention, AEs with potential to differentially affect the pregnant woman and her fetus should have separate maternal and fetal grading criteria. Four such AEs were proposed: Haemorrhage in pregnancy, Preterm premature rupture of membranes, Chorioamnionitis and Anaemia of pregnancy (Table 2). For example, preterm premature rupture of membranes (PPROM) at 20 weeks of gestation in the absence of chorioamnionitis would likely have significant impact on the fetus causing life-threatening pulmonary hypoplasia, but less impact on the pregnant woman’s health.

The Steering Group agreed fetal AE definitions related to specific organs and systems (Table 2), namely abnormalities in the fetus detectable by imaging in the gastrointestinal, renal, brain or musculoskeletal systems, including fetal movement disorders and fetal fluid collection. Fetal AEs related to fetal heart rate abnormalities (bradycardia or tachyarrhythmia) and cardiac function abnormalities were defined. More non-specific AEs defined abnormal fetal growth, fetal neoplasm and a ‘catch-all’ term for fetal structural abnormalities: not otherwise classified. Fetal AE definitions were developed...
specifically for AEs related to fetal interventions (Table 2). Fetal intraoperative injury was defined as unintended damage to the fetus occurring as a result of a fetal interventional procedure, but excluding the effects of fetal haemorrhage. Separately two fetal AEs related to local or remote haemorrhage during (fetal procedural haemorrhage) or occurring after a fetal procedure (fetal post-procedural haemorrhage) were proposed; both AE definitions also included fetomaternal haemorrhage.

Finally the Steering Group agreed on a draft set of AE severity criteria which were then subjected to the two stage Delphi consensus (data not shown).

### Table 2 The maternal and fetal AE terms for which definitions and severity grading criteria were developed

| Maternal AEs                                      | Fetal AEs                                      |
|---------------------------------------------------|------------------------------------------------|
| Haemorrhage in pregnancy                         | Haemorrhage in pregnancy                      |
| Preterm premature rupture of membranes           | Preterm premature rupture of membranes         |
| Chorioamnionitis                                  | Chorioamnionitis                               |
| Anaemia of pregnancy                              | Anaemia of pregnancy                           |
| Gestational hypertension                         | Fetal fluid collection<sup>a</sup>             |
| Pre-eclampsia                                     | Fetal bradycardia: non-labour<sup>a</sup>      |
| Eclampsia                                         | Fetal tachycardia: non-labour<sup>a</sup>      |
| Premature labour                                  | Cardiac function abnormalities<sup>a</sup>    |
| Puerperal infection                               | Fetal brain scan abnormal<sup>a</sup>          |
| Postpartum haemorrhage (primary)                  | Fetal gastrointestinal tract imaging abnormal<sup>b</sup> |
| Retained placenta or membranes                    | Fetal musculoskeletal imaging abnormal<sup>a</sup> |
| Amniotic fluid embolism                           | Fetal renal imaging abnormal<sup>a</sup>      |
|                                                   | Fetal movement disorders<sup>a</sup>           |
|                                                   | Fetal neoplasm<sup>a</sup>                    |
|                                                   | Fetal structural abnormalities: not otherwise classified<sup>a</sup> |
|                                                   | Abnormal fetal growth<sup>a</sup>             |
|                                                   | Fetal intraoperative injury<sup>a</sup>        |
|                                                   | Procedural haemorrhage<sup>a</sup>            |
|                                                   | Post-procedural haemorrhage<sup>a</sup>       |

Abbreviation: AE, adverse event.
<sup>a</sup>Added to the Medical Dictionary for Regulatory Activities terms list.

The fetal AE terms were adapted to integrate with existing MedDRA High Level and Lowest Level Terms (Table S4). For example, the originally proposed AE 'fetal renal abnormalities' was changed to 'fetal renal imaging abnormal' to fit an existing higher level MedDRA term 'fetal and neonatal imaging procedures'. The modified AE terms were approved by the Steering Group and added to the MedDRA terms list v19.0 (Table 2).

### 3.2.2 Integration into MedDRA terminology

The Steering Group met the Chief Medical Officer for the MedDRA MSSO to integrate the new terminology into MedDRA (September 2015). The proposal for AEs differentially affecting the mother and the fetus to be recorded as separate AEs, for example, 'fetal chorioamnionitis' and 'maternal chorioamnionitis', could not be accommodated within the structure of MedDRA. Instead, it was agreed that one AE would be recorded ('chorioamnionitis') but that the maternal and fetal severity would be recorded separately.

3.2.3 | Review by Patient Public Advisory Group

The PPAG review supported the general principles of assessing AE severity in pregnancy proposed by the Steering Group and the preliminary generic and specific AE severity grading criteria. The group also identified broader considerations on the AE assessment in pregnancy (Table 3). Among these were the potential psychological effect of fetal AEs on the pregnant woman, the wider psychological impact of participating in clinical trials during pregnancy and considering the effect of AEs on future fertility and pregnancies. The PPAG indicated the importance of carefully documenting patient choices such as termination of pregnancy or palliative care after birth for those fetuses with life-threatening abnormalities.
TABLE 3  Patient and Public Advisory Group recommendations for best practice in clinical trials of maternal and fetal therapies

- Define the timing of AE assessment in the clinical trial protocol. Depending on the intervention short-term, medium-term, and/or long-term AEs may be appropriate and the severity grading may change across these timepoints. Ideally report as much as possible, potentially as supplementary online information.
- Record information on antenatal decisions to terminate the pregnancy or to have only palliative neonatal care after birth. State in the clinical trial protocol how these outcomes will be analysed and consider them part of the same group when analysing data and measuring mortality.
- Mode of labour onset and mode of delivery are outcomes that should be reported, including whether the mode of delivery is likely to impact on decisions regarding delivery in future pregnancies (i.e., women undergoing classical Caesarean section or open fetal surgery are advised to delay another pregnancy for a year to avoid labour).
- Assess the psychological impact of the intervention on the pregnant woman and her partner including the psychological impact of any fetal AEs. Evaluate using validated measures in comparison with an ‘untreated’ group with the same condition.
- Where possible include costs in clinical trial funding applications for psychological support for pregnant women and their partners and, especially in phase I trials, consider qualitative assessment of the women’s experience.
- Include in the clinical trial protocol assessment methods to capture data about the fetal response to an intervention, including indications of fetal pain or stress. Appropriate measures are likely to vary depending on whether the intervention involves the fetus directly (fetal surgery) or indirectly (maternal medication).
- Capture data on subsequent fertility and pregnancies over a time period proportionate and relevant to the intervention under investigation. This should include whether women were trying to conceive, and their pregnancy outcomes and complications if they were successful.

3.3  Phase 3: refining and finalising the criteria

3.3.1  Modified Delphi consensus process

The first round had 45 participants from 33 countries in the maternal AE survey and 63 participants from 34 countries in the fetal AE survey. For the second round, 39 participants (87%) completed the maternal AE survey, and 54 participants (86%) completed the fetal AE survey (Table S5). Table S6 lists the levels of agreement in each round; final definitions and criteria are in Table S7.

3.3.2  Maternal adverse events

Of the 12 proposed maternal AEs, 11 definitions reached consensus in the first survey; the final definition reached consensus in the second survey. Sixty-three of the 74 criteria (85%) reached consensus in the first survey; a further 9 reached consensus in the second survey (total 96%). One criterion, ‘haemorrhage in pregnancy: maternal’ was broken down further in the second survey, with two of three components reaching consensus. The two outstanding issues resolved by consensus within the final Steering Group Meeting were (1) classifying ‘haemorrhage in pregnancy’ with blood loss of 250–1000 ml and no signs of clinical shock as a grade 3 (severe) maternal AE, and (2) classifying ‘retained placenta or membranes’ requiring minimal, local or non-invasive intervention to deliver the placenta following vaginal birth as a grade 2 (moderate) maternal AE. This achieved consistency with the CTCAE generic guidelines whereby a grade 3 (severe) AE is medically significant and/or requires hospitalisation, whereas a grade 2 (moderate) AE requires minimal, local or non-invasive intervention.

3.3.3  Fetal adverse events

Of the 19 proposed fetal AEs, 18 definitions reached consensus in the first survey; the final definition and three modified definitions reached consensus in the second survey. Fifty-nine of the 73 criteria (80%) reached consensus in the first survey; a further eight reached consensus in the second survey (total 92%). An additional criterion for ‘preterm premature rupture of membranes: fetal’ was added to the second survey and reached consensus.

Three outstanding issues were resolved by consensus within the final Steering Group Meeting. Firstly, for both the generic grading criteria and for ‘fetal tachyarrhythmia’ the proposed grade 2 (moderate) criterion ‘resolves spontaneously with low risk of long-term consequences’ did not reach consensus, with most participants in the second round (54% and 59%, respectively) considering that it should be downgraded to grade 1 (mild). The Steering Group agreed to this downgrading. Secondly, three of the proposed grade 3 (severe) criteria for ‘fetal brain imaging abnormal’ failed to reach consensus (cystic changes, abnormal cortical development and hydrocephalus). These were removed as specific criteria and would need to be graded according to the generic criteria if they occurred. Finally, the criterion ‘imaging appearance highly suggestive of bowel necrosis or perforation’, proposed as a grade 3 (severe) AE for ‘fetal gastrointestinal tract imaging abnormal’, achieved only 65% agreement in the first but 69% in the second round; the Steering Group agreed to retain this as a grade 3 (severe) AE.

4  DISCUSSION

4.1  Main findings

We describe the development of the most comprehensive set of maternal and fetal AE definitions and severity grading criteria available, which can guide investigators and clinicians in assessing the severity of AEs so as to increase the quality of safety information. By reviewing international guidelines and consensus statements, building on the existing CTCAE framework, liaising with MedDRA and seeking consensus from international experts through a modified Delphi consensus process we have made this terminology as robust as possible.
For clinical trials, recording and reporting AEs using standardised severity grading terminology allows comparison of safety data between clinical trials. For first-in-human or early-phase trials in particular, AE grading is vital to facilitate dose escalation by allowing the categorisation of Dose Limiting Toxicity (DLT) events in the mother and fetus, so as to derive the target toxicity level and then to define the Maximum Tolerated Dose (MTD). Without suitable AE grading and criteria for the mother and the fetus, it is not possible to define these trial endpoints, rendering early phase trial safety assessment impossible. The deficiency of appropriate regulatory language available to describe safety assessment until now may have contributed to the lack of investment in novel therapeutics for pregnancy diseases. A recent example of this phenomenon is the SarsCoV2 pandemic, a current and urgent situation in which the exclusion of pregnant women and those breastfeeding from many clinical trials of treatment or vaccination for COVID-19 has left a vacuum of information. This means that women and their healthcare providers have had to make treatment decisions without the appropriate safety information.65 We hope that this terminology will now be adopted by trialists, industry and regulatory authorities to address this deficit in treatments for pregnant women and their fetuses.

4.2 Interpretation

The MFAET version 1.0 system can also be used to standardise recording and severity grading of AEs in untreated populations, to provide comparison and valuable reproducible contextual ‘control’ data with which to interpret safety and AEs in interventional trials. The EVERREST prospective study, for example, is defining characteristics of pregnancies affected by severe early onset fetal growth restriction, generating control data for a future first-in-human intervention trial of maternal gene therapy.66 The terminology is being used to derive the dose escalation plan of the Phase I clinical trial protocol. In addition, this terminology can be used simply to study safety in cohort studies of maternal and/or fetal intervention. A recent example used fetal AE MedDRA terms to define maternal and fetal complications after fetal surgery for myelomeningocele.68

The Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) report to the US Secretary, Health and Human Services Congress, September 2018, identified the difficulties with developing safe and effective therapies for pregnant and lactating women, due to gaps in knowledge and research from limited existing scientific literature.67 These new AE definitions and grading in MFAET version 1.0 will provide the nomenclature to fulfil their objectives which include prioritising data collection on therapeutic products.

Our approach of grading the severity of AEs separately for the pregnant woman and the fetus allows for greater detail and nuance in AE reporting. Many severe or life-threatening fetal AEs have little physical impact on the mother and may have been difficult to capture in the past given the previously limited fetal AE terms and severity grading criteria. However, assessing fetal AEs raises specific challenges; current methods of investigating the fetus through imaging and fetal heart rate monitoring, and predicting short- and long-term prognosis are rarely sufficient to differentiate between mild and moderate events and between severe and life-threatening events. This is why many of the fetal AEs only have severity criteria defined for grade 2 (moderate) and grade 4 (life-threatening), with grade 3 remaining undefined. A recent study published in 2019 developed a more limited set of AEs in relation to thoraco-amniotic shunting. The authors adopted a similar generic grading system for fetal AEs, and again acknowledged the potential for maternal AEs such as haemorrhage to independently act as a fetal AE.70

4.3 Strengths and limitations

The strength of our process is that we carefully examined existing terminology and literature to identify gaps in AE assessment for the mother and the fetus. Our Steering Group and Delphi consensus members included multiple key stakeholders involved in developing maternal and fetal drugs, devices and surgical interventions. We ensured international participation in the process with academic and non-academic clinicians and researchers, industry representatives, scientists, midwifery and parent representatives.

This terminology should however not be considered final or exhaustive. Future refinement and expansion, such as that undertaken by other AE severity grading systems, will continue to improve these criteria with revised versions to be released in the future. More criteria are likely to be added as the process matures, fetal anaemia being one such criterion that has not yet been included. Until the next version is available, trialists can apply the generic criteria to estimate the severity for AEs that may not be currently included in MFAET version 1.0. We did not specifically develop an AE definition for analysis of Cardiotocography (CTG, non-stress test ‘NST’) as this will be accommodated in the fetal heart rate AEs (Fetal Bradycardia and Fetal Tachyarrhythmia). Future versions may need to accommodate new methods of fetal assessment including objective fetal movement monitoring, computerised CTG analysis of short-term variability (STV) and machine learning algorithms.

Laboratory-based AEs for the pregnant woman such as abnormal liver or thyroid function are not included in any existing grading criteria such as CTCAE, DAIDS, etc., and will require future development. Deriving laboratory-based AEs for the fetus depends on data from invasive sampling of amniotic fluid, placental villi, fetal blood or urine which carries a risk of miscarriage or preterm labour. Historical data is available and has been used to develop non-invasive ultrasound Doppler methods to diagnose fetal anaemia.71 As analysis of fetal circulating DNA, RNA and proteins in the maternal blood advances, it is possible that fetal laboratory-based AEs will be developed to further assess fetal well-being.72,73

The goal of a standardised AE severity scale is to reduce subjectivity in severity assessments and thus reduce interobserver
variability. We are currently planning prospective validation studies of agreement among observers in different countries for the generic and specific severity criteria for maternal and fetal AEs.

5 CONCLUSION

This novel set of 12 maternal and 19 fetal AE definitions and severity grading criteria (MFAET version 1.0) has been developed through an international modified Delphi consensus process. This terminology fills a vital gap in maternal and fetal translational medicine research, supporting the development of therapies for pregnant women, a neglected patient group. We recommend their use to achieve systematic and consistent AE grading and reporting within and between clinical trials in pregnancy. Only by doing this will clinical trials provide a meaningful understanding of safety and the risk/benefit for mothers and their fetuses, lifting the mystique and reducing reluctance to undertake studies in pregnancy.

ACKNOWLEDGEMENTS

Dr Judy Harrison, Chief Medical Officer, MedDRA; Eva Rump, MedDRA; Brian O'Hare, MedDRA; Mr Pranav Pandya, University College London Hospitals, UK; Professor Graça Almeida-Porada, Wake Forest University, USA; Professor Howard Berger, St. Michael's Hospital and University of Toronto, Canada; Dr Amarnath Bhide, St George's University Hospitals, UK; Professor Frank Bloomfield, University of Auckland, New Zealand; Dr Antonio Borrell, Hospital Clinic Barcelona, Spain; Professor Peter Brocklehurst, University of Birmingham, UK; Professor Pavel Calda, Charles University and General University Hospital in Prague, Czech Republic; Dr Jenny Carter, King's College London, UK; Professor Lucy Chappell, King's College London, UK; Mr Mark Denbow, University Hospitals Bristol NHS Foundation Trust, UK; Professor Fiona Denison, University of Edinburgh, UK; Professor Jan Derks, University Medical Centre Utrecht, Netherlands; Professor Roland Devlieger, Universitair Ziekenhuis Leuven, Belgium; Emeritus Professor Leila Duley, University of Nottingham, UK; Dr Thomas Everett, Leeds General Infirmary, UK; Dr Diana Farmer, University of California Davis, USA; Dr Chris Gale, Chelsea and Westminster NHS Trust and Imperial College London, UK; Dr Wessel Ganzevort, University of Amsterdam, The Netherlands; Professor Lut Geerts, University of Stellenbosch, South Africa; Dino Giussani, University of Cambridge, UK; Dr Sanne Gordijn, University of Groningen, The Netherlands; Associate Professor Katie Groom, University of Auckland, New Zealand; Professor Eric Janssens, University College London, UK; Professor Edward D Johnstone, University of Manchester, UK; Dr Ashok Khurana, The Ultrasound Lab, New Delhi, India; Professor Marian Knight, University of Oxford, UK; Professor Sailesh Kumar, Mater Mothers' Hospital, Royal Brisbane & Women's Hospital and University of Queensland, Australia; Paula Lavandeira-Fernandez, University College London Hospitals, UK; Dr Kwok-yin Leung, Gleneagles Hospital, Hong Kong; Dr Wing-Cheong Leung, Kwong Wah Hospital, Hong Kong; Associate Professor Liesbeth Lewi, University Hospitals Leuven and KULeuven, Belgium; Dr Fionnuala Mone, Birmingham Women's Hospital, UK; Professor Suzanne Miller, Monash University, Australia; Dr R Katie Morris, University of Birmingham, UK; Professor Nicole Ochsenbein-Kööble, University Hospital Zurich, Switzerland; Professor Keelin O'Donoghue, University College Cork, Ireland; Professor Lucas Otaño, Instituto Universitario Hospital Italiano y Universidad de Buenos Aires, Argentina; Professor Christopher Porada, Wake Forest University, USA; Associate Professor Joanne Said, Sunshine Hospital and University of Melbourne, Australia; Professor Regine Steegers-Theunissen, Erasmus University Rotterdam, Netherlands; Mr Nigel Simpson, Leeds Teaching Hospitals NHS Trust and University of Leeds, UK; Professor Peter Stone, University of Auckland, New Zealand; Professor Luming Sun, Shanghai First Maternity & Infant Hospital of Tongji University, China; Professor Derek Tuffnell, Bradford Teaching Hospitals NHS Foundation Trust, UK; Professor Peter von Deldersen, King's College London, UK; Professor Susan Walker, University of Melbourne, Australia; Professor Euan Wallace, Monash University, Australia; Dr James Webbe, Imperial College London; Professor Boaz Weisz, Sheba Medical Center, Israel; Professor Emeritus R Douglas Wilson, University of Calgary, Canada. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305823 (EVERREST), the EGA Hospital Charity, and through an Innovative Engineering for Health award (GIFT-Surg) by the Wellcome Trust [WT101957] and Engineering and Physical Sciences Research Council (EPSRC) [NS/A000027/1].

Anna L David, Neil Marlow and Donald M Peebles are supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Kurt Hecher and Anke Diemert are funded by the German Research Foundation (DFG). Jan Deprest is funded by the Great Ormond Street Hospital Charity.

The funders played no role in conducting the research or writing the manuscript.

CONFLICT OF INTEREST

Rebecca N Spencer: none.
Kurt Hecher: none.
Gill Norman: From 2010 to 2018, I was an unpaid trustee/director of the UK charity Antenatal Results and Choices (ARC). My academic research is funded by NIHR through the Greater Manchester ARC and Cochrane Wounds; I have previously received funding from NIHR through other funding streams.
Karel Marsal: none.
Jan Deprest: none.
Alan Flake: reports consulting fees and receives Sponsored Research funding from Vitara Biomedical (Artificial Womb technology) and holds multiple patents related to the Artificial Womb technology.
Francesc Figueras: none.
Christoph Lees: none.
Steve Thornton: Trustee to Charities, consultancy for commercial organisations.
Kathleen Beach: none.
Marcy Powell: none.
Fatima Crispi: none.
Anke Diemert: none.
Neil Marlow: reports personal fees from Takeda, personal fees from Novartis, outside the submitted work.
Donald M Peebles: none.
Magnus Westgren: none.
Helena Gardiner: none.
Eduard Gratacos: none.
Jana Brodzski: none.
Albert Batista: none.
Helen Turier: none.
Mehali Patel: none.
Beverley Power: none.
James Power: none.
Gillian Yaz: none.
Anna L. David: Trustee to charities; reports consulting fees for Esperare Foundation, Geneva, Switzerland, a private not-for-profit developing a prenatal therapy for a congenital skin disease; member of the Maternal Health Project Group of ABPI (The Association of British Pharmaceutical Industry) since November 2020 (unpaid); member of the Policy Commission on Effective, Safe and Accessible Medicines in Pregnancy, University of Birmingham since September 2021 (unpaid).

DATA AVAILABILITY STATEMENT
All data generated by this study are presented in the manuscript.

ORCID
Jan Deprest https://orcid.org/0000-0002-4920-945X
Anna L. David https://orcid.org/0000-0002-0199-6140

REFERENCES
1. Turner MA, Kenny L, Alhfrevic Z. Challenges in designing clinical trials to test new drugs in the pregnant woman and fetus. Clin Perinatol. 2019;46(2):399-416. doi:10.1016/j.clp.2019.02.015
2. David A, Thornton S, Sucitliffe A, et al. Scientific Impact Paper No. 50. Developing New Pharmaceutical Treatments for Obstetric Conditions. London, UK: RCOG; 2015. https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip-50.pdf
3. Feuerstein IM, Jenkins MR, Kornstein SG, et al. Working together to address women’s health in research and drug development: summary of the 2017 Women’s Health Congress Preconference Symposium. J Women’s Health. 2002;27(10):1195-1203. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425923/
4. Illamola SM, Bucci-Rechweg C, Costantine MM, Tsilou E, Sherwin CM, Zajicek A. Inclusion of pregnant and breastfeeding women in research – efforts and initiatives. Br J Clin Pharmacol. 2018;84(2):215-222. doi:10.1111/bcp.13438
5. Kaye DK. The moral imperative to approve pregnant women’s participation in randomized clinical trials for pregnancy and newborn complications. Philos Ethics Humit Med. 2019;14(1):11. doi:10.1186/s13010-019-0081-8
6. Fisk NM, McKee M, Atun R. Relative and absolute addressability of global disease burden in maternal and perinatal health by investment in R&D. Trop Med Int Health. 2011;16(6):662-668. doi:10.1111/j.1365-3156.2011.02778.x
7. European Medicines Agency. ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. European Medicines Agency; 1995. https://www.ema.europa.eu/en/documents/scientific-guide/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf
8. Food and Drug Administration Department of Health and Human Services. Code of Federal Regulations Title 21. Subchapter D: Drugs for Human Use. 2019. https://www.ecfr.gov/current/title-21/chapter-1/subchapter-D
9. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_Sx7.pdf
10. Division of Acquired Immunodeficiency Syndrome (DAID), Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Addendum 1: Female Genital Grading Table for Use in Microbiologic Studies. US: National Institute of Allergy and Infectious Disease; 2004. Accessed October, 2014. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Addendum_1_Female_Genital_Grading_Table_v1_Nov_2007.pdf
11. GlaxoSmithKline Adverse Event Severity Grading Criteria Used to Assess Safety in the Clinical Trials of Retosibian. 2015.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213. doi:10.1097/01.sla.0000133083.54934
13. Gipson DS, Kirkendall ES, Gumbs-Petty B, et al. Development of a pediatric adverse events terminology. Pediatrics. 2017;139(1). doi:10.1542/peds.2016-0985
14. Salaets T, Turner MA, Short M, et al. Development of a neonatal adverse event severity scale through a Delphi consensus approach. Arch Dis Child. 2019;104(12):1167-1173. doi:10.1136/archdischild-2019-317399
15. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38(3):655-662. doi:10.1007/s11096-016-0257-x
16. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009.
17. World Health Organisation, Evaluating the Quality of Care for Severe Pregnancy Complications: The WHO Near-Miss Approach for Maternal Health. Geneva, Switzerland: World Health Organisation; 2011. https://www.who.int/reproductivehealth/publications/monitoring/9789241502221/en/
18. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 63: Antepartum Haemorrhage. London, UK: RCOG; 2011. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_63.pdf
19. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 52: Prevention and Management of Postpartum Haemorrhage. London, UK: RCOG; 2009. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.14178
20. Lennox C, Marr L. Scottish Confidential Audit of Severe Maternal Morbidity: Reducing Avoidable Harm – 10th Annual Report. Healthcare Improvement Scotland; 2014. https://www.healthcareimprovement.scotland.org/his/doc.ashx?docid=7c7edd1b-d87e-4271-805b-da80ffbe60f&version=1
21. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage.
22. World Health Organisation. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. 2012.

23. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Management of Postpartum Haemorrhage (PPH). Melbourne, Australia: RANZCOG; 2011. Accessed March 2015. https://ranzco.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/ Women%27s%20Health/Statement%20and%20guidelines/ClinicalObstetrics/Management-of-Postpartum-Haemorrhage-[C-Obs-43]-Review-July-2017.pdf?ext=.pdf

24. Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Diagnostik und Therapie perioperativer Blutungen [Diagnosis and Therapy for Perioperative Bleeding]. Germany: DGGG; 2010.

25. Leduc D, Senikas V, Lalone AB, et al. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynecol Can. 2009;31(10):980-993. doi:10.1016/s1710-2163(11634329-8

26. Goffinet F. [Postpartum hemorrhage: methods used and topics discussed]. J Gynecol Obstet Biol Reprod. 2004;338 Suppl:457-458.

27. Abdul Leduc D, Senikas V, Lalonde AB, et al. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynecol Can. 2009;31(10):980-993. doi:10.1016/s1710-2163(16)34329-8

28. Goffinet F. [Postpartum hemorrhage: methods used and topics discussed]. J Gynecol Obstet Biol Reprod. 2004;338 Suppl:457-458.

29. New Zealand Ministry of Health. National Consensus Guideline for Treatment of Postpartum Haemorrhage. Wellington, New Zealand: New Zealand Ministry of Health; 2013. Accessed March 2015. https://www.health.govt.nz/publication/national-consensus-guideline-treatment-postpartum-haemorrhage

30. Kommission Qualitatssicherung der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe. [Current treatment options in postpartum hemorrhage. Expert correspondence no. 26 of 26 May 2009].

31. Royal College of Obstetricians and Gynaecologists. Prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynaecol Obstet. 2012;117(2):108-118. doi:10.1016/j.ijgo.2012.03.001

32. National Collaborating Centre for Women’s and Children’s Health. Prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynaecol Obstet. 2012;117(2):108-118. doi:10.1016/j.ijgo.2012.03.001

33. Finer LB, Jean P, Haddad M, et al. Active management of the third stage of labor: prevention and treatment of postpartum hemorrhage. J Obstet Gynecol Can. 2009;31(10):980-993. doi:10.1016/s1710-2163(16)34329-8

34. American College of Obstetricians and Gynecologists. Green-top Guideline No. 44: Preterm Prelabour Rupture of Membranes. London, UK: RCOG; 2010. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg44/

35. World Health Organisation. Iron Deficiency Anaemia: Assessment, Prevention and Control. Geneva, Switzerland: WHO; 2001. Accessed March 2015. https://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/

36. American College of Obstetricians and Gynecologists. Practice Bulletin No. 95: anemia in pregnancy. Obstet Gynecol. 2008;112(1):201-207. doi:10.1097/AOG.0b013e3181809c0d

37. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97-104. doi:10.1016/j.preghy.2014.02.001

38. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 2013;3(1):44-47. doi:10.1016/j.preghy.2012.11.001

39. Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynecol Can. 2014;36(5):416-438. doi:10.1016/j.s1701-2163(15)30588-0

40. National Collaborating Centre for Women’s and Children’s Health. NICE Clinical Guideline 127. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. RCOG; 2010.

41. World Health Organisation. WHO Recommendations for the Prevention and Treatment of Pre-eclampsia and Eclampsia. 2011.

42. Lindheimer MD, Taler SJ, Cunningham FG. ASH position paper: hypertensive in pregnancy. J Clin Hypertens. 2009;11(4):214-225. doi:10.1111/j.1751-7176.2009.00085.x

43. Fishman SG, Gelber SE. Evidence for the clinical management of choioamnionitis. Semin Fetal Neonatal Med. 2012;17(1):46-50. doi:10.1016/j.siny.2011.09.002
55. Fahey JO. Clinical management of intra-amniotic infection and chorioamnionitis: a review of the literature. *J Midwifery Women’s Health*. 2008;53(3):227-235. doi:10.1016/j.jmwh.2008.01.001
56. Chapman E, Reveiz L, Illanes E, Bonfill Cosp X. Antibiotic regimens for management of intra-amniotic infection. *Cochrane Database Syst Rev*. 2014(12):CD010976. doi:10.1002/14651858.CD010976.pub2
57. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 64b: Bacterial Sepsis Following Pregnancy. London, UK: RCOG; 2010. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg_64b/
58. Hussein J, Walker L. Chapter 8: puerperal sepsis in low- and middle-income settings: past, present and future. In: Kehoe S, Neilson J, Norman J, eds. *Maternal and Infant Deaths: Chasing Millenium Development Goals 4 & 5*. RCOG; 2010.
59. Knight M, Berg C, Brocklehurst P, et al. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. *BMC Pregnancy Childbirth*. 2012;12:7. doi:10.1186/1471-2933-12-7
60. Kramer MS, Rouleau J, Liu S, Bartholomew S, Joseph K. Amniotic fluid embolism: incidence, risk factors, and impact on perinatal outcome. *BJOG*. 2012;119(7):874-879. doi:10.1111/j.1471-0528.2012.03323.x
61. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 56: Maternal Collapse in Pregnancy and the Puerperium. London, UK: RCOG; 2011. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_56.pdf
62. National Collaborating Centre for Women’s and Children’s Health. *NICE Clinical Guideline 190: Intrapartum Care for Pregnant Women and Babies*. UK: National Institute for Health and Care Excellence; 2014. https://www.nice.org.uk/guidance/cg190/resources/intrapartum-care-for-healthy-women-and-babies-pdf-35109866447557
63. United States Department of Health and Human Services. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine. US: Center for Biologics Evaluation and Research; 2007. Accessed October, 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/ucm091977.pdf
64. Division of Microbiology and Infectious Diseases (DMID). Adult Toxicity Table; 2007. Accessed October, 2014. https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf
65. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 2010. Accessed October 2014. US: U.S. Department of Health and Human Services; 2010. https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf
66. Taylor MM, Kobeissi L, Kim C, et al. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. *Lancet Glob Health*. 2021;9(3):e366-e371. doi:10.1016/S2214-109X(20)30484-8
67. Spencer R, Ambler G, Brodyszki J, et al. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. *BMC Pregnancy Childbirth*. 2017;17(1):43. doi:10.1186/s12884-017-1226-7
68. Vonzun L, Kahr MK, Noll F, et al. Systematic classification of maternal and fetal intervention-related complications following open fetal myelomeningocele repair – results from a large prospective cohort. *BJOG*. 2020;128:1184-1191. https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/1471-0528.16593
69. Eunice Kennedy Shriver National Institute of Child Health and Human Development. *Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC)*. 2018. https://www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf
70. Takahashi Y, Sago H, Ishii K, Murakoshi T, Murotsuki J, Nakata M. New terminology for adverse events of fetal therapy: Re-evaluation of the thoraco-amniotic shunting in a Japanese study. *J Obstet Gynaecol Res*. 2019;45(2):251-257.
71. Martinez-Portilla RJ, Lopez-Felix J, Hawkins-Villareal A, et al. Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2019;54(6):722-731. doi:10.1002/uog.20273
72. Tong S, Joy Kaitu’u-Lino T, Walker SP, McDonald TM. Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. *Prenat Diagn*. 2019;39(11):947-957. doi:10.1002/pd.5525
73. Pernemalm M, Sandberg A, Zhu Y, et al. In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta. *Elife*. 2019;8. doi:10.7554/eLife.41608

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Spencer RN, Hecher K, Norman G, et al. Development of standard definitions and grading for Maternal and Fetal Adverse Event Terminology. *Prenat Diagn.* 2022;42(1):15-26. https://doi.org/10.1002/pd.6047